0001209191-15-085940.txt : 20151217
0001209191-15-085940.hdr.sgml : 20151217
20151217193217
ACCESSION NUMBER: 0001209191-15-085940
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151215
FILED AS OF DATE: 20151217
DATE AS OF CHANGE: 20151217
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kite Pharma, Inc.
CENTRAL INDEX KEY: 0001510580
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
BUSINESS PHONE: (310) 824-9999
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sproule Rizwana F
CENTRAL INDEX KEY: 0001609644
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36508
FILM NUMBER: 151294974
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-12-15
0
0001510580
Kite Pharma, Inc.
KITE
0001609644
Sproule Rizwana F
C/O KITE PHARMA, INC.
2225 COLORADO AVENUE
SANTA MONICA
CA
90404
0
1
0
0
VP Regulatory Affairs
Common Stock
2015-12-15
4
M
0
9567
1.35
A
12508
D
Common Stock
2015-12-15
4
S
0
3373
62.70
D
9135
D
Common Stock
2015-12-15
4
S
0
2410
63.73
D
6725
D
Common Stock
2015-12-15
4
S
0
3352
64.64
D
3373
D
Common Stock
2015-12-15
4
S
0
432
65.38
D
2941
D
Employee Stock Option (Right to Buy)
1.35
2015-12-15
4
M
0
9567
0.00
D
2024-03-24
Common Stock
9567
123464
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.17 to $63.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.17 to $64.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.24 to $65.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.24 to $65.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
25% of the 200,000 shares subject to the stock option vested and became exercisable on January 6, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
/s/ Dave Tanen, Attorney-in-Fact
2015-12-15